Marché des tests de fonction pulmonaire en Amérique du Nord – Tendances et prévisions de l’industrie jusqu’en 2031

Demande de table des matières Demande de table des matières Parler à un analysteParler à un analyste Acheter maintenantAcheter maintenant Renseignez-vous avant d'acheterRenseignez-vous avant Exemple de rapport gratuitExemple de rapport gratuit

Marché des tests de fonction pulmonaire en Amérique du Nord – Tendances et prévisions de l’industrie jusqu’en 2031

  • Medical Devices
  • Publish Reports
  • Sep 2024
  • North America
  • 350 Pages
  • Nombre de tableaux : 116
  • Nombre de figures : 34

North America Pulmonary Function Testing Market

Taille du marché en milliards USD

TCAC :  % Diagram

Diagram Période de prévision
2024 –2031
Diagram Taille du marché (année de référence)
USD 1.53 Billion
Diagram Taille du marché (année de prévision)
USD 2.47 Billion
Diagram TCAC
%
DiagramPrincipaux acteurs du marché
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5 < /li>

>Marché des tests de la fonction pulmonaire en Amérique du Nord, par type (matériel, services et logiciels), type de patient (pédiatrique, adulte et gériatrique), application (maladie pulmonaire obstructive et maladie pulmonaire restrictive), utilisateur final (hôpital, cliniques spécialisées, laboratoires de diagnostic, établissements de soins à domicile et autres) - Tendances et prévisions de l'industrie jusqu'en 2031.

Marché des tests de la fonction pulmonaire en Amérique du Nord

Analyse et perspectives du marché des tests de fonction pulmonaire en Amérique du Nord

Le marché des tests de la fonction pulmonaire est stimulé par la prévalence croissante des maladies respiratoires, les avancées technologiques et la demande croissante de médecine personnalisée. Les principales tendances du marché comprennent l'adoption croissante des appareils PFT au point de service, la demande croissante d'appareils PFT sans fil et portables et l'accent croissant mis sur la médecine personnalisée et la médecine de précision . Cependant, le marché est également confronté à des défis tels que l'accessibilité limitée des appareils PFT dans certaines régions, le coût élevé des appareils et consommables PFT, la complexité de l'interprétation et de l'analyse PFT et la sensibilisation limitée aux PFT parmi les prestataires de soins de santé et les patients.

Data Bridge Market Research analyse que le marché nord-américain des tests de fonction pulmonaire devrait atteindre 2,47 milliards USD d'ici 2031, contre 1,53 milliard USD en 2023, avec un TCAC de 6,1 % au cours de la période de prévision de 2024 à 2031.

Rapport métrique

Détails

Période de prévision

2024 à 2031

Année de base

2023

Années historiques

2022 (personnalisable pour 2016-2021)

Unités quantitatives

Chiffre d'affaires en milliards USD

Segments couverts

Type (matériel, services et logiciels), type de patient (pédiatrique, adulte et gériatrique), application (maladie pulmonaire obstructive et maladie pulmonaire restrictive), utilisateur final (hôpital, cliniques spécialisées, laboratoires de diagnostic, établissements de soins à domicile et autres)

Pays couverts

États-Unis, Canada et Mexique

Acteurs du marché couverts

VYAIRE MEDICAL, INC., Teleflex Incorporated, CAIRE, Inc., COSMED srl, Schiller AG, PULMONE ADVANCED MEDICAL DEVICE, ndd Medical Technologies, KoKo PFT, ECO MEDICS, Morgan Scientific, Inofab Health, Data Sciences International, IngMar Medical, JK Medical System Pvt. Ltd, MEDLINE, VITALOGRAPH et CONTEC MEDICAL SYSTEMS CO., LTD, entre autres

Définition du marché

Le test de fonction pulmonaire (TFP) est une évaluation complète de la fonction pulmonaire, utilisée pour diagnostiquer et surveiller les maladies respiratoires telles que la bronchopneumopathie chronique obstructive (BPCO), l'asthme et la bronchite chronique . La définition du marché du TFP comprend une gamme de tests, notamment la capacité vitale forcée (CVF), le volume expiratoire forcé (VEMS), le rapport VEMS/CVF, la ventilation volontaire maximale (VVM) et la capacité de diffusion (DLCO). Le TFP est généralement effectué à l'aide d'un spiromètre, un appareil qui mesure le volume et le débit d'air inspiré et expiré par le patient.

Dynamique du marché des tests de fonction pulmonaire en Amérique du Nord

Cette section traite de la compréhension des moteurs, des opportunités, des contraintes et des défis du marché. Tout cela est discuté en détail ci-dessous :      

Conducteurs

  • Increasing Prevalence of Respiratory Disease

The increasing prevalence of respiratory diseases is a significant driver for the global pulmonary function testing market. Conditions such as Chronic Obstructive Pulmonary Disease (COPD) and asthma are becoming more common due to factors like aging populations, environmental pollutants, and lifestyle changes. As these diseases grow in prevalence, there is a heightened demand for accurate and reliable diagnostic tools to manage and monitor these conditions. Pulmonary function tests are crucial for diagnosing respiratory diseases, assessing their severity, and tracking disease progression. This increased need for regular and precise testing drives the market, as healthcare providers and patients seek advanced PFT technologies to improve respiratory health outcomes and provide effective management strategies.

  • Early Detection of Respiratory Diseases

The increasing respiratory disorders of early detection is a key driver for the global Pulmonary Function Testing (PFT) market. The surge in respiratory disorders such as asthma, Chronic Obstructive Pulmonary Disease (COPD), and cystic fibrosis fuels the demand for pulmonary function testing. The pulmonary function tests play a crucial role in enabling early detection and efficient management of respiratory conditions, thereby improving patient outcomes and quality of life through timely intervention and treatment.

Opportunity

  • Rapid Technological Advancements

The development of innovative PFT devices, particularly those integrated with AI, enhances diagnostic accuracy and efficiency, offering more reliable results in identifying pulmonary diseases. Comprehensive testing systems are becoming increasingly user-friendly and portable, making them accessible to a broader range of healthcare settings. The integration with digital health technologies, such as AI and telemedicine, allows for advanced diagnostic accuracy and predictive analytics, as well as remote monitoring through connected PFT devices, expanding the reach and impact of these tools. Advanced sensor technologies, including high-sensitivity and wearable sensors, provide continuous monitoring and real-time data collection, enabling more precise and timely interventions.

Challenges/Restraints

  • High Cost of Testing Equipment

The high cost of pulmonary function testing equipment hampers market growth by restricting access for smaller healthcare facilities and hindering penetration in certain regions. The substantial investment required for purchasing and maintaining sophisticated PFT devices poses financial challenges for healthcare facilities, particularly in developing regions. This economic barrier restricts the widespread adoption and use of PFT technologies, affecting overall market growth and accessibility. Addressing these cost challenges is essential for enhancing the reach and impact of pulmonary function testing worldwide.

  • Lack of Standardization and Variability in Test Results

A notable lack of uniform standards leads to variability in device specifications and test protocols, which can hinder the consistency and comparability of test results across different equipment. This variability complicates efforts to integrate PFT devices with Electronic Health Record (EHR) systems, making seamless data exchange and comprehensive patient records more difficult to achieve. Without standardized protocols, ensuring that data from various PFT devices can be accurately and efficiently integrated into EHR systems remains a complex task.

Recent Developmevnts

  • In April 2024, Clario's acquisition of ArtiQ enhances its Respiratory Solutions portfolio by integrating advanced AI capabilities. This strategic move combines Clario's expertise with ArtiQ’s innovative technology to improve test quality and accelerate data processing in clinical trials. The acquisition, alongside Inofab Health, solidifies Clario's leadership in respiratory care and broadens its AI-driven clinical solutions
  • In September 2023, PulmOne has launched the MiniBox+ in China, showcasing it to pulmonologists at the 2023 Annual Congress of the Chinese Thoracic Society (CTS) through our distributor HTDK. The introduction was met with great enthusiasm from attendees. Check out the exciting video highlights from the event
  • In May 2023, Geratherm Medical AG, was honored as a "hidden champion" by the State Development Corporation of Thuringia (LEG). The recognition highlights the company's significant role in medical technology and its global market presence. Board member Christian Frick expressed gratitude for the accolade, noting the company's innovation in medical diagnostics, lung function measurement, stroke prevention, and incubator systems, which positions it well for future growth
  • In May 2023, Vitalograph, a leader in respiratory diagnostics, has expanded its portfolio with the introduction of the Vitalograph tremoflo C-100 Oscillometer at the ATS International Conference. Developed in partnership with Thorasys, this innovative device detects small airway impairment through simple tidal breathing, enhancing the diagnosis of asthma and COPD. The tremoflo C-100 integrates with the Vitalograph Spirotrac platform, offering a comprehensive view of respiratory health and supporting accurate, portable testing in various settings
  • In April 2023, Ingmar Medical introduced RespiSim Software Version 4.3 a key advancement, including improved scenario import/export, reduced simulation lag, and enhanced platform stability. These updates significantly elevate usability and performance, making it a vital tool for respiratory therapy education and training.
  • In September 2022, IngMar Medical launches RespiSim eLearning, a subscription-based platform providing affordable, realistic ventilation training. Featuring a Virtual Ventilator and a suite of Cleveland Clinic courses, this new offering supports hybrid and remote education, fostering a community of educators dedicated to enhancing patient outcomes

North America Pulmonary Function Testing Market Scope

The North America pulmonary function testing market is segmented into four notable segments based on type, patient type, application, and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.

Type

  • Hardware
  • Software
  • Services

On the basis of service, the North America pulmonary function testing market is segmented into hardware, software, and services.

Patient Type

  • Adult
  • Geriatric
  • Pediatric

On the basis of patient type, the North America pulmonary function testing market is segmented into adult, geriatric, and pediatric.

Application

  • Obstructive Lung Disease
  • Restrictive Lung Disease

On the basis of application, the North America pulmonary function testing market is segmented into obstructive lung disease, restrictive lung disease.

End User

  • Hospital
  • Specialty Clinics
  • Diagnostics Laboratories
  • Home Care Settings
  • Others

On the basis of end user, the North America pulmonary function testing market is segmented into hospital, specialty clinics, diagnostics laboratories, home care settings, and others.

North America Pulmonary Function Testing Market Regional Analysis/Insights

The North America pulmonary function testing market is segmented into four notable segments based on type, patient type, application, and end user.

The countries covered in this market report are U.S., Canada, and Mexico

U.S. is expected to dominate in the North America region due to presence of market players and improving development and research in healthcare sector. The region's early tech adoption and mature market contribute to a strong demand for advanced solutions.

The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of large services company and their challenges faced due to large or scarce competition from local and domestic players and the impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and North America Pulmonary Function Testing Market Share Analysis

Le paysage concurrentiel du marché des tests de fonction pulmonaire en Amérique du Nord fournit des détails sur les concurrents. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements en R&D, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement du produit, les approbations de produits, la largeur et l'étendue du produit, la domination des applications et la courbe de survie du type de produit. Les points de données ci-dessus fournis ne concernent que l'orientation de l'entreprise sur le marché.

Français Les principaux acteurs du marché opérant sur le marché sont VYAIRE MEDICAL, INC., Teleflex Incorporated, CAIRE, Inc., COSMED srl, Schiller AG, PULMONE ADVANCED MEDICAL DEVICE, ndd Medical Technologies, KoKo PFT, ECO MEDICS, Morgan Scientific, Inofab Health, Data Sciences International, IngMar Medical, JK Medical System Pvt. Ltd, MEDLINE, VITALOGRAPH et CONTEC MEDICAL SYSTEMS CO., LTD entre autres.


SKU-

Accédez en ligne au rapport sur le premier cloud mondial de veille économique

  • Tableau de bord d'analyse de données interactif
  • Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
  • Accès d'analyste de recherche pour la personnalisation et les requêtes
  • Analyse de la concurrence avec tableau de bord interactif
  • Dernières actualités, mises à jour et analyse des tendances
  • Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Demande de démonstration

Table des matières

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE NORTH AMERICA PULMONARY FUNCTION TESTING MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 MARKET APPLICATION COVERAGE GRID

2.8 PRODUCT LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PORTER’S FIVE FORCES

4.2 PESTEL ANALYSIS

5 REGULATORY FRAMEWORK

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASING PREVALENCE OF RESPIRATORY DISEASES

6.1.2 EARLY DETECTION OF RESPIRATORY DISEASES

6.1.3 GROWING GERIATRIC POPULATION

6.1.4 INCREASING PRODUCT LAUNCHES AND EMERGENCE OF HOME TESTING DEVICES

6.2 RESTRAINTS

6.2.1 HIGH COST OF TESTING EQUIPMENT

6.2.2 TECHNOLOGICAL LIMITATION OF TESTING DEVICES

6.3 OPPORTUNITIES

6.3.1 RAPID TECHNOLOGICAL ADVANCEMENTS

6.3.2 RISING STRATEGIC INITIATIVES

6.3.3 GOVERNMENT INITIATIVES AND REIMBURSEMENT POLICIES

6.3.4 PRODUCT DEVELOPMENT FOR AT-HOME TESTING

6.4 CHALLENGES

6.4.1 LACK OF STANDARDIZATION AND VARIABILITY IN TEST RESULTS

6.4.2 LACK OF SKILLED PROFESSIONALS

7 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET, BY TYPE

7.1 OVERVIEW

7.2 HARDWARE

7.2.1 PFT DEVICES

7.2.2 PFT ACCESSORIES & CONSUMABLES

7.2.2.1 Spirometry

7.2.2.2 Lung Volume in Unit/ Plethysmography Test

7.2.2.3 Gas Exchange Testing

7.2.2.4 Cardiopulmonary Exercise Test (CPET)

7.2.2.5 Pulse Oximetry Test

7.2.2.6 Diffusion Capacity Test

7.2.2.7 Maximal Voluntary Ventilation

7.2.2.8 Oxygen Titration Test

7.2.2.9 Respiratory Muscle Function

7.2.2.10 Bronchial Provocation Test

7.2.2.11 High Altitude Simulation Testing

7.2.3 OTHERS

7.2.3.1 3.2. Direct Tender

7.2.3.2 3.2. Retail Sales

7.2.4 OTHERS

7.3 SOFTWARE

7.4 SERVICES

8 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET, BY PATIENT TYPE

8.1 OVERVIEW

8.2 ADULT

8.2.1 MALE

8.2.2 FEMALE

8.3 GERIATRIC

8.3.1 MALE

8.3.2 FEMALE

8.4 PEDIATRIC

8.4.1 MALE

8.4.2 FEMALE

9 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET, BY APPLICATION

9.1 OVERVIEW

9.2 OBSTRUCTIVE LUNG DISEASE

9.2.1 ASTHMA

9.2.2 CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

9.2.3 BRONCHIECTASIS

9.2.4 CYSTIC FIBROSIS

9.3 RESTRICTIVE LUNG DISEASE

9.3.1 LUNG CANCER

9.3.2 INTERSTITIAL LUNG DISEASE

9.3.3 AMYOTROPHIC LATERAL SCLEROSIS (ALS)

9.3.4 SCOLIOSIS

9.3.5 SARCOIDOSIS

9.3.6 MUSCULAR DYSTROPHY

10 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET, BY END USER

10.1 OVERVIEW

10.2 HOSPITALS

10.2.1 PUBLIC

10.2.2 PRIVATE

10.3 SPECIALTY CLINICS

10.4 DIAGNOSTICS LABORATORIES

10.5 HOME CARE SETTINGS

10.6 OTHERS

11 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET, BY REGION

11.1 NORTH AMERICA

11.1.1 U.S.

11.1.2 CANADA

11.1.3 MEXICO

12 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: COMPANY LANDSCAPE

12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

13 SWOT ANALYSIS

14 COMPANY PROFILES

14.1 VYAIRE MEDICAL, INC.

14.1.1 COMPANY SNAPSHOT

14.1.2 COMPANY SHARE ANALYSIS

14.1.3 PRODUCT PORTFOLIO

14.1.4 RECENT DEVELOPMENTS

14.2 TELEFLEX INCORPORATED

14.2.1 COMPANY SNAPSHOT

14.2.2 REVENUE ANALYSIS

14.2.3 COMPANY SHARE ANALYSIS

14.2.4 PRODUCT PORTFOLIO 166

14.2.5 RECENT DEVELOPMENT 166

14.3 CAIRE INC.

14.3.1 COMPANY SNAPSHOT

14.3.2 COMPANY SHARE ANALYSIS

14.3.3 PRODUCT PORTFOLIO

14.3.4 RECENT DEVELOPMENTS

14.4 COSMED SRL

14.4.1 COMPANY SNAPSHOT

14.4.2 COMPANY SHARE ANALYSIS

14.4.3 PRODUCT PORTFOLIO

14.4.4 RECENT DEVELOPMENTS

14.5 SCHILLER AG

14.5.1 COMPANY SNAPSHOT

14.5.2 COMPANY SHARE ANALYSIS

14.5.3 PRODUCT PORTFOLIO

14.5.4 RECENT DEVELOPMENTS

14.6 CHEST M.I., INC.

14.6.1 COMPANY SNAPSHOT

14.6.2 PRODUCT PORTFOLIO

14.6.3 RECENT DEVELOPMENTS

14.7 CLARITY MEDICAL

14.7.1 COMPANY SNAPSHOT

14.7.2 PRODUCT PORTFOLIO

14.7.3 RECENT DEVELOPMENT

14.8 CONTEC MEDICAL SYSTEMS CO., LTD

14.8.1 COMPANY SNAPSHOT

14.8.2 PRODUCT PORTFOLIO

14.8.3 RECENT DEVELOPMENT

14.9 DATA SCIENCES INTERNATIONAL.

14.9.1 COMPANY SNAPSHOT

14.9.2 PRODUCT PORTFOLIO

14.9.3 RECENT DEVELOPMENTS

14.1 ECO MEDICS

14.10.1 COMPANY SNAPSHOT

14.10.2 PRODUCT PORTFOLIO

14.10.3 RECENT DEVELOPMENTS

14.11 FUKUDA SANGYO CO., LTD.

14.11.1 COMPANY SNAPSHOT

14.11.2 PRODUCT PORTFOLIO

14.11.3 RECENT DEVELOPMENT

14.12 GANSHORN MEDIZIN ELECTRONIC GMBH

14.12.1 COMPANY SNAPSHOT

14.12.2 PRODUCT PORTFOLIO

14.12.3 RECENT DEVELOPMENTS

14.13 GERATHERM MEDICAL AG

14.13.1 COMPANY SNAPSHOT

14.13.2 REVENUE ANALYSIS

14.13.3 PRODUCT PORTFOLIO

14.13.4 RECENT DEVELOPMENT

14.14 INGMAR MEDICAL

14.14.1 COMPANY SNAPSHOT

14.14.2 PRODUCT PORTFOLIO

14.14.3 RECENT DEVELOPMENT

14.15 INOFAB HEALTH (A CLARIO COMPANY)

14.15.1 COMPANY SNAPSHOT

14.15.2 PRODUCT PORTFOLIO

14.15.3 RECENT DEVELOPMENT

14.16 JK MEDICAL SYSTEMS PVT LTD.

14.16.1 COMPANY SNAPSHOT

14.16.2 PRODUCT PORTFOLIO

14.16.3 RECENT DEVELOPMENTS

14.17 KOKO, PFT

14.17.1 COMPANY SNAPSHOT

14.17.2 PRODUCT PORTFOLIO

14.17.3 RECENT DEVELOPMENTS

14.18 MEC

14.18.1 COMPANY SNAPSHOT

14.18.2 PRODUCT PORTFOLIO

14.18.3 RECENT DEVELOPMENT

14.19 MEDICAL EQUIPMENT EUROPE GMBH

14.19.1 COMPANY SNAPSHOT

14.19.2 PRODUCT PORTFOLIO

14.19.3 RECENT DEVELOPMENTS

14.2 MEDLINE

14.20.1 COMPANY SNAPSHOT

14.20.2 PRODUCT PORTFOLIO

14.20.3 RECENT DEVELOPMENT

14.21 MORGAN SCIENTIFIC

14.21.1 COMPANY SNAPSHOT

14.21.2 PRODUCT PORTFOLIO

14.21.3 RECENT DEVELOPMENTS

14.22 NDD MEDICAL TECHNOLOGIES

14.22.1 COMPANY SNAPSHOT

14.22.2 PRODUCT PORTFOLIO

14.22.3 RECENT DEVELOPMENTS

14.23 PULMONE ADVANCED MEDICAL DEVICES

14.23.1 COMPANY SNAPSHOT

14.23.2 PRODUCT PORTFOLIO

14.23.3 RECENT DEVELOPMENT

14.24 RECORDERS & MEDICARE SYSTEMS PRIVATE LIMITED

14.24.1 COMPANY SNAPSHOT

14.24.2 PRODUCT PORTFOLIO

14.24.3 RECENT DEVELOPMENT

14.25 SCIREQ

14.25.1 COMPANY SNAPSHOT

14.25.2 PRODUCT PORTFOLIO

14.25.3 RECENT DEVELOPMENT

14.26 SIBEL, S.A.U

14.26.1 COMPANY SNAPSHOT

14.26.2 PRODUCT PORTFOLIO

14.26.3 RECENT DEVELOPMENT

14.27 VITALOGRAPH

14.27.1 COMPANY SNAPSHOT

14.27.2 PRODUCT PORTFOLIO

14.27.3 RECENT DEVELOPMENT

15 QUESTIONNAIRE

16 RELATED REPORTS

Liste des tableaux

TABLE 1 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 2 NORTH AMERICA HARDWARE IN PULMONARY FUNCTION TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 3 NORTH AMERICA HARDWARE IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 4 NORTH AMERICA PFT DEVICES IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 5 NORTH AMERICA PFT DEVICES IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (VOLUME IN UNIT)

TABLE 6 NORTH AMERICA PFT DEVICES IN PULMONARY FUNCTION TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)

TABLE 7 NORTH AMERICA PFT ACCESSORIES & CONSUMABLES IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 8 NORTH AMERICA PFT ACCESSORIES & CONSUMABLES IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (VOLUME IN UNIT)

TABLE 9 NORTH AMERICA MOUTHPIECE IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 10 NORTH AMERICA ADULT IN PULMONARY FUNCTION TESTING MARKET, BY SIZE, 2022-2031 (USD THOUSAND)

TABLE 11 NORTH AMERICA NOSE CLIP IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 12 NORTH AMERICA HARDWARE IN PULMONARY FUNCTION TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 13 NORTH AMERICA HARDWARE IN PULMONARY FUNCTION TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 14 NORTH AMERICA HARDWARE IN PULMONARY FUNCTION TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 15 NORTH AMERICA SOFTWARE IN PULMONARY FUNCTION TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 16 NORTH AMERICA SERVICES IN PULMONARY FUNCTION TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 17 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 18 NORTH AMERICA ADULT IN PULMONARY FUNCTION TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 19 NORTH AMERICA ADULT IN PULMONARY FUNCTION TESTING MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 20 NORTH AMERICA GERIATRIC IN PULMONARY FUNCTION TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 21 NORTH AMERICA GERIATRIC IN PULMONARY FUNCTION TESTING MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 22 NORTH AMERICA PEDIATRIC IN PULMONARY FUNCTION TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 23 NORTH AMERICA PEDIATRIC IN PULMONARY FUNCTION TESTING MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 24 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)

TABLE 25 NORTH AMERICA OBSTRUCTIVE LUNG DISEASE IN PULMONARY FUNCTION TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 26 NORTH AMERICA OBSTRUCTIVE LUNG DISEASE IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 27 NORTH AMERICA RESTRICTIVE LUNG DISEASE IN PULMONARY FUNCTION TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 28 NORTH AMERICA RESTRICTIVE LUNG DISEASE IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 29 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 30 NORTH AMERICA HOSPITAL IN PULMONARY FUNCTION TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 31 NORTH AMERICA HOSPITAL IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 32 NORTH AMERICA SPECIALTY CLINICS IN PULMONARY FUNCTION TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 33 NORTH AMERICA DIAGNOSTICS LABORATORIES IN PULMONARY FUNCTION TESTING, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 34 NORTH AMERICA HOME CARE SETTINGS IN PULMONARY FUNCTION TESTING, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 35 NORTH AMERICA OTHERS IN PULMONARY FUNCTION TESTING, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 36 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 37 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 38 NORTH AMERICA HARDWARE IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 39 NORTH AMERICA PFT DEVICES IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 40 NORTH AMERICA PFT DEVICES IN PULMONARY FUNCTION TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)

TABLE 41 NORTH AMERICA PFT ACCESSORIES & CONSUMABLES IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 42 NORTH AMERICA MOUTHPIECE IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 43 NORTH AMERICA ADULT IN PULMONARY FUNCTION TESTING MARKET, BY SIZE, 2022-2031 (USD THOUSAND)

TABLE 44 NORTH AMERICA NOSE CLIP IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 45 NORTH AMERICA HARDWARE IN PULMONARY FUNCTION TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 46 NORTH AMERICA HARDWARE IN PULMONARY FUNCTION TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 47 NORTH AMERICA RETAIL SALES IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 48 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 49 NORTH AMERICA ADULT IN PULMONARY FUNCTION TESTING MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 50 NORTH AMERICA GERIATRIC IN PULMONARY FUNCTION TESTING MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 51 NORTH AMERICA PEDIATRIC IN PULMONARY FUNCTION TESTING MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 52 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)

TABLE 53 NORTH AMERICA OBSTRUCTIVE LUNG DISEASE IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 54 NORTH AMERICA RESTRICTIVE LUNG DISEASE IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 55 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 56 NORTH AMERICA HOSPITAL IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 57 U.S. PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 58 U.S. HARDWARE IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 59 U.S. PFT DEVICES IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 60 U.S. PFT DEVICES IN PULMONARY FUNCTION TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)

TABLE 61 U.S. PFT ACCESSORIES & CONSUMABLES IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 62 U.S. MOUTHPIECE IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 63 U.S. ADULT IN PULMONARY FUNCTION TESTING MARKET, BY SIZE, 2022-2031 (USD THOUSAND)

TABLE 64 U.S. NOSE CLIP IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 65 U.S. HARDWARE IN PULMONARY FUNCTION TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 66 U.S. HARDWARE IN PULMONARY FUNCTION TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 67 U.S. RETAIL SALES IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 68 U.S. PULMONARY FUNCTION TESTING MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 69 U.S. ADULT IN PULMONARY FUNCTION TESTING MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 70 U.S. GERIATRIC IN PULMONARY FUNCTION TESTING MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 71 U.S. PEDIATRIC IN PULMONARY FUNCTION TESTING MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 72 U.S. PULMONARY FUNCTION TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)

TABLE 73 U.S. OBSTRUCTIVE LUNG DISEASE IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 74 U.S. RESTRICTIVE LUNG DISEASE IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 75 U.S. PULMONARY FUNCTION TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 76 U.S. HOSPITAL IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 77 CANADA PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 78 CANADA HARDWARE IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 79 CANADA PFT DEVICES IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 80 CANADA PFT DEVICES IN PULMONARY FUNCTION TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)

TABLE 81 CANADA PFT ACCESSORIES & CONSUMABLES IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 82 CANADA MOUTHPIECE IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 83 CANADA ADULT IN PULMONARY FUNCTION TESTING MARKET, BY SIZE, 2022-2031 (USD THOUSAND)

TABLE 84 CANADA NOSE CLIP IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 85 CANADA HARDWARE IN PULMONARY FUNCTION TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 86 CANADA HARDWARE IN PULMONARY FUNCTION TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 87 CANADA RETAIL SALES IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 88 CANADA PULMONARY FUNCTION TESTING MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 89 CANADA ADULT IN PULMONARY FUNCTION TESTING MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 90 CANADA GERIATRIC IN PULMONARY FUNCTION TESTING MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 91 CANADA PEDIATRIC IN PULMONARY FUNCTION TESTING MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 92 CANADA PULMONARY FUNCTION TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)

TABLE 93 CANADA OBSTRUCTIVE LUNG DISEASE IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 94 CANADA RESTRICTIVE LUNG DISEASE IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 95 CANADA PULMONARY FUNCTION TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 96 CANADA HOSPITAL IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 97 MEXICO PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 98 MEXICO HARDWARE IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 99 MEXICO PFT DEVICES IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 100 MEXICO PFT DEVICES IN PULMONARY FUNCTION TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)

TABLE 101 MEXICO PFT ACCESSORIES & CONSUMABLES IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 102 MEXICO MOUTHPIECE IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 103 MEXICO ADULT IN PULMONARY FUNCTION TESTING MARKET, BY SIZE, 2022-2031 (USD THOUSAND)

TABLE 104 MEXICO NOSE CLIP IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 105 MEXICO HARDWARE IN PULMONARY FUNCTION TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 106 MEXICO HARDWARE IN PULMONARY FUNCTION TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 107 MEXICO RETAIL SALES IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 108 MEXICO PULMONARY FUNCTION TESTING MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 109 MEXICO ADULT IN PULMONARY FUNCTION TESTING MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 110 MEXICO GERIATRIC IN PULMONARY FUNCTION TESTING MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 111 MEXICO PEDIATRIC IN PULMONARY FUNCTION TESTING MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 112 MEXICO PULMONARY FUNCTION TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)

TABLE 113 MEXICO OBSTRUCTIVE LUNG DISEASE IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 114 MEXICO RESTRICTIVE LUNG DISEASE IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 115 MEXICO PULMONARY FUNCTION TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 116 MEXICO HOSPITAL IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

Liste des figures

FIGURE 1 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 8 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: DBMR MARKET POSITION GRID

FIGURE 9 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: SEGMENTATION

FIGURE 11 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET, BY TYPE

FIGURE 12 EXECUTIVE SUMMARY

FIGURE 13 STRATEGIC DECISIONS

FIGURE 14 INCREASING PREVALENCE OF RESPIRATORY DISEASES IS DRIVING THE GROWTH OF THE NORTH AMERICA PULMONARY FUNCTION TESTING MARKET FROM 2024 TO 2031

FIGURE 15 THE HARDWARE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA PULMONARY FUNCTION TESTING MARKET IN 2024 AND 2031

FIGURE 16 DROC ANALYSIS

FIGURE 17 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: BY TYPE, 2023

FIGURE 18 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: BY TYPE, 2024-2031 (USD THOUSAND)

FIGURE 19 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: BY TYPE, CAGR (2024-2031)

FIGURE 20 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: BY TYPE, LIFELINE CURVE

FIGURE 21 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: BY PATIENT TYPE, 2023

FIGURE 22 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: BY PATIENT TYPE, 2024-2031 (USD THOUSAND)

FIGURE 23 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: BY PATIENT TYPE, CAGR (2024-2031)

FIGURE 24 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: BY PATIENT TYPE, LIFELINE CURVE

FIGURE 25 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: BY APPLICATION 2023

FIGURE 26 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: BY APPLICATION, 2024-2031 (USD THOUSAND)

FIGURE 27 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: BY APPLICATION, CAGR (2024-2031)

FIGURE 28 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 29 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: BY END USER 2023

FIGURE 30 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: BY END USER, 2024-2031 (USD THOUSAND)

FIGURE 31 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: END USER, CAGR (2024-2031)

FIGURE 32 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: END USER, LIFELINE CURVE

FIGURE 33 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: SNAPSHOT (2023)

FIGURE 34 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: COMPANY SHARE 2023 (%)

Voir les informations détaillées Right Arrow

Méthodologie de recherche

La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.

La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.

Personnalisation disponible

Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.

Questions fréquemment posées

The market is segmented based on , By Type (Hardware, Services, and Software), Patient Type (Pediatric, Adult, and Geriatric), Application (Obstructive Lung Disease and Restrictive Lung Disease), End User (Hospital, Specialty Clinics, Diagnostics Laboratories, Home Care Settings, and Others) - Industry Trends and Forecast to 2031. .
The North America Pulmonary Function Testing Market size was valued at USD 1.53 USD Billion in 2023.
The North America Pulmonary Function Testing Market is projected to grow at a CAGR of 6.1% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada, and Mexico.